We’re glad you’re enjoying
Pig Health Today.


Access is free but you’ll need to
register to view more content.
Already registered? Sign In
X
OPEN IN APPOPEN IN APP
Download the report!Continue to Site >
or wait 7 secs

REPORTS

Collect articles and features into your own report to read later, print or share with others
CANCEL

Create a new report

Report title (required) Brief description (optional)
CREATE
CANCEL

SRD pathogens remain highly susceptible to key antimicrobials

Download the PDF

Pathogens commonly associated with swine respiratory disease (SRD) remain highly susceptible to key veterinary antimicrobials, according to the latest results from a Zoetis surveillance program.1

The highest rates of susceptibility were found with Actinobacillus pleuropneumoniae isolates, which were all 100% susceptible to ceftiofur, tulathromycin and florfenicol, said Michael Sweeney, senior principal scientist, Zoetis.

All Pasteurella multocida isolates were also 100% susceptible to ceftiofur, and all Bordetella bronchiseptica isolates were 100% susceptible to tulathromycin (Table 1), Sweeney said.

There were a couple of exceptions, he reported. A. pleuropneumoniae, P. multocida and Streptococcus suis had low susceptibility to tetracycline, and B. bronchiseptica was completely resistant to ampicillin and had low susceptibility to florfenicol.

These latest results are based on testing of more than 2,400 isolates from 2016 to 2019. However, the rates of susceptibility are similar to what has been observed over the past 21 years of the Zoetis surveillance program, Sweeny said, and added that “little to no multi-drug resistance has been found.”

Supports responsible antimicrobial use

The Zoetis surveillance program, initiated in 1998, annually collects and analyzes isolates obtained from geographically diverse veterinary diagnostic laboratories in the US and Canada. The isolates are from animals with naturally occurring SRD.

Susceptibility is determined based on the minimal inhibitory concentration (MIC) — the lowest concentration of each antimicrobial that prevents visible growth of a bacterium. Testing is conducted with strict adherence to the Clinical and Laboratory Standards Institute (CLSI) standardized methods.

“We crunch the data down to MIC50 and MIC90 values, and to susceptible, intermediate or resistant , based on available CLSI-endorsed breakpoints,” Sweeney said. The results, presented to the FDA’s Center for Veterinary Medicine, are also shared with the laboratories that provide the isolates, at veterinary conferences and are periodically published in veterinary journals.

Surveillance helps identify resistance trends and fosters an improved understanding of antimicrobial resistance. It also supports responsible antimicrobial use, Sweeney said.

Encouraging results

“Within our advanced surveillance program at Zoetis, we continue to see low resistance in the pig sector, and that’s in contrast to findings among other types of livestock, where we find higher rates of antimicrobial resistance,” he said.

Asked why there’s low resistance among SRD pathogens affecting swine, Sweeney said he doesn’t know the answer but thinks it might be due to management and perhaps all-in/all-out production practices. It may also be a reflection of the swine industry’s commitment to the responsible use of antimicrobials, which Sweeney said he finds “very encouraging.”

Click table to enlarge

 


1 Data on file. Study Report No. A671Z-US-19-165. Zoetis, LLC

 

DISCOVERIES, Issue 25
Discoveries is a series of research news reports written by the editors of Pig Health Today on behalf of the US Pork Business of Zoetis.

EXS-00039
April 2021

 

 

 




Posted on June 24, 2021
Share It
Pathogens commonly associated with swine respiratory disease (SRD) remain highly susceptible to key veterinary antimicrobials, according to the latest results from a Zoetis surveillance program.
Click an icon to share this information with your industry contacts.
  • Share
    Email
    Email
    Facebook
    Facebook
    Twitter
    Twitter
    LinkedIn
    LinkedIn
    Print
    Print

    Favorites

    Read Later

    My Reports